title: Curing cervical cancer or preventing it: A case of opportunity cost in the long run?
authors.affiliation: CESAV, Center for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Via Camozzi 3, 24020 Ranica, Italy.
authors.forename: Katelijne
authors.initials: K
authors.lastname: van de Vooren
authors.affiliation: CESAV, Center for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Via Camozzi 3, 24020 Ranica, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Curto
authors.affiliation: CESAV, Center for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Via Camozzi 3, 24020 Ranica, Italy. Electronic address: livio.garattini@marionegri.it.
authors.forename: Livio
authors.initials: L
authors.lastname: Garattini
mesh_terms: D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000191:economics*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics*; D000068258:Bevacizumab; D005260:Female; D017048:Health Care Costs; D006291:Health Policy; D006801:Humans; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000191:economics*; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000517:prevention & control* / Q000628:therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D053918:Papillomavirus Vaccines; D000068258:Bevacizumab
keywords: Bevacizumab; Cervical cancer; HPV vaccines; Opportunity cost